|
|
||||||||



Departments of
*
Microbiology and Immunology and
Pathology, University of Texas Medical Branch, Galveston, TX 77555;
Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390; and
Sealy Center for Molecular Sciences, University of Texas Medical Branch Genomics Core, Galveston, TX 77555
Experimental autoimmune myasthenia gravis (EAMG) is severe in RIIIS/J mice, despite a significant B cell immunodeficiency and a massive TCR V
gene deletion. Severity of EAMG in RIIIS/J mice is greater than MHC-identical (H-2r) B10.RIII mice, suggesting the influence of non-MHC genes as an EAMG-potentiating factor in this strain. To delineate the role of deleted TCR V
genes in RIIIS/J mice, we obtained (RIIIS/J x B10.RIII)F1 (V
b/c) x RIIIS/J (V
c) backcross mice using Mendelian genetic methods and immunized them with acetylcholine receptor. EAMG susceptibility was not elevated in mice with V
c genotype having 70% V
gene deletion. Next, we performed microarray analysis on 12,488 spleen cDNAs obtained from spleens of naive RIIIS/J and B10.RIII mice. In RIIIS/J mice, 263 cDNAs were overexpressed and 303 cDNAs were underexpressed greater than 2-fold, compared with B10.RIII mice. TCR gene expression was augmented, whereas NK receptor, C1q, and C3 gene expressions were diminished in RIIIS/J mice. RIIIS/J mice also had increased lymph node T cell counts, elevated serum anti-AChR Ab levels, and serum C3 and C1q-conjugated circulating immune complex levels. A direct correlation between increased serum C1q-conjugated circulating immune complex levels and disease severity was observed in RIIIS/J mice.
This article has been cited by other articles:
![]() |
H. Yang, E. Tuzun, D. Alagappan, X. Yu, B. G. Scott, A. Ischenko, and P. Christadoss IL-1 Receptor Antagonist-Mediated Therapeutic Effect in Murine Myasthenia Gravis Is Associated with Suppressed Serum Proinflammatory Cytokines, C3, and Anti-Acetylcholine Receptor IgG1 J. Immunol., August 1, 2005; 175(3): 2018 - 2025. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |